NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02563054,A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer,https://clinicaltrials.gov/study/NCT02563054,,COMPLETED,"This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer. The anticipated time on study treatment is at least 6 weeks and continued up to disease progression, and the target sample size is 300 individuals.",NO,Gastric Cancer,DRUG: 5-Fluorouracil|DRUG: Capecitabine|DRUG: Cisplatin,"Time to disease progression, Up to approximately 7.3 years","Objective tumor response rate, Up to approximately 7.3 years|Overall survival, Up to approximately 7.3 years|Duration of response, Up to approximately 7.3 years|Time to response, Up to approximately 7.3 years|Incidence of adverse events, Up to approximately 7.3 years",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,316,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ML17032,2003-04,2010-08,2010-08,2015-09-29,,2016-11-02,"Buenos Aires, C1264AAA, Argentina|Buenos Aires, C1270AAE, Argentina|Rosario, S2000PBJ, Argentina|Tegucigalpa, Belize|Barretos, 14780-400, Brazil|Curitiba, 80060-150, Brazil|Florianopolis, 88034-000, Brazil|Fortaleza, 60741-420, Brazil|Porto Alegre, 90020-090, Brazil|Sao Paulo, 05403-010, Brazil|Sorocaba, 18035-300, Brazil|Beijing, 100021, China|Beijing, 100036, China|Guangdong, 510060, China|Guangdong, 510515, China|Hubei, 430030, China|Jiangsu, 210009, China|Jiangxi, 330000, China|Shandong, 250117, China|Shanghai, 200003, China|Shanghai, 200092, China|Shanghai, 200433, China|Suzhou, 215006, China|Tianjin, 300060, China|Bogota, Colombia|Guatemala City, 01015, Guatemala|Hong Kong, 852, Hong Kong|Hong Kong, Hong Kong|Seoul, 135-170, Korea, Republic of|Seoul, 135-720, Korea, Republic of|Seoul, 138-736, Korea, Republic of|Seoul, 405-760, Korea, Republic of|Kuala Lumpur, 56000, Malaysia|Merida, 97070, Mexico|Mexico City, 14000, Mexico|Mexico City, 14080, Mexico|Mexico Df, 06726, Mexico|Panama City, 83-0669, Panama|Callao, Peru|Lima, 13, Peru|Kazan, 420029, Russian Federation|Moscow, 115478, Russian Federation|St Petersburg, 197758, Russian Federation|UFA, 450054, Russian Federation|Montevideo, 11600, Uruguay",
